chemomab ltd. is a clinical-stage biotech company, focusing on discovery and development of innovative therapeutics for fibrosis-related diseases with large unmet need. chemomab is making great strides with its novel cm-101 proprietary platform, which hinders the fundamental function of the soluble chemokine ccl24 as a regulator of major inflammatory and fibrotic pathways in multiple fibrosis-related disorders. cm-101, the company’s lead clinical candidate, is a first-in-class monoclonal antibody that targets ccl24. chemomab has shown that cm-101 interferes with the underlying biology of fibrosis using a novel and differentiated mechanism of action. chemomab is actively advancing cm-101 into phase 2 studies to treat patients with liver fibrosis (primary sclerosing cholangitis and non-alcoholic steatohepatitis) and patients suffering from skin and lung fibrosis (systemic sclerosis).
Company profile
Ticker
CMMB, NA
Exchange
Website
CEO
Neil Cohen
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
Anchiano Therapeutics Ltd., BioCancell Ltd.
SEC CIK
Corporate docs
Subsidiaries
Chemomab Ltd. • Chemomab Therapeutics, Inc. • Chemomab Therapeutics Israel Ltd. ...
CMMB stock data
Latest filings (excl ownership)
20-F
2023 FY
Annual report (foreign)
28 Mar 24
6-K
Chemomab Therapeutics Announces Year End and Fourth Quarter 2023 Financial Results
7 Mar 24
6-K
Chemomab Announces Completion of Patient Enrollment in CM-101 Phase 2 Primary
3 Jan 24
6-K
Current report (foreign)
9 Nov 23
EFFECT
Notice of effectiveness
6 Nov 23
CORRESP
Correspondence with SEC
1 Nov 23
F-3/A
Shelf registration (foreign) (amended)
30 Oct 23
F-3
Shelf registration (foreign)
16 Oct 23
6-K
Current report (foreign)
14 Aug 23
6-K
Current report (foreign)
8 Aug 23
Latest ownership filings
SC 13D/A
OrbiMed Israel BioFund GP Limited Partnership
11 Mar 24
SC 13D/A
OrbiMed Israel BioFund GP Limited Partnership
15 Nov 23
4
Nissim Darvish
5 Jul 23
4
Jill M. Quigley
20 Jun 23
4
Sigal Fatal
16 Jun 23
3
Sigal Fatal
5 Jun 23
4
Alan Charles Moses
23 Mar 23
4
Claude Nicaise
23 Mar 23
4
Neil Harris Cohen
23 Mar 23
4
Nissim Darvish
23 Mar 23
Financial summary
Quarter (USD) | Mar 23 | Dec 22 | Sep 22 | Jun 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 20.84 mm | 20.84 mm | 20.84 mm | 20.84 mm | 20.84 mm | 20.84 mm |
Cash burn (monthly) | (no burn) | (no burn) | 2.91 mm | 2.65 mm | 2.40 mm | 1.99 mm |
Cash used (since last report) | n/a | n/a | 37.18 mm | 33.86 mm | 30.60 mm | 25.38 mm |
Cash remaining | n/a | n/a | -16.34 mm | -13.02 mm | -9.76 mm | -4.54 mm |
Runway (months of cash) | n/a | n/a | -5.6 | -4.9 | -4.1 | -2.3 |
Institutional ownership, Q2 2023
13F holders | Current |
---|---|
Total holders | 15 |
Opened positions | 7 |
Closed positions | 0 |
Increased positions | 0 |
Reduced positions | 1 |
13F shares | Current |
---|---|
Total value | 5.44 bn |
Total shares | 35.58 mm |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
Thiel Peter | 22.63 mm | $1.71 bn |
Access Industries | 5.06 mm | $381.15 mm |
Gabriel Capital Management | 3.09 mm | $21.30 mm |
OrbiMed Israel BioFund GP Limited Partnership | 2.27 mm | $6.67 mm |
Orbimed Advisors | 2.24 mm | $2.95 bn |
Ikarian Capital | 213.39 k | $279.54 mm |
Kestra Private Wealth Services | 31.24 k | $41.08 mm |
Boothbay Fund Management | 26.53 k | $34.89 mm |
Geode Capital Management | 11.74 k | $15.38 mm |
Rhumbline Advisers | 3.01 k | $3.94 mm |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
16 Jun 23 | Jill M. Quigley | Option to Purchase American Depositary Shares American Depositary Shares | Grant | Acquire A | No | No | 1.71 | 6,857 | 11.73 k | 20,497 |
14 Jun 23 | Sigal Fatal | Option to Purchase American Depositary Shares American Depositary Shares | Grant | Acquire A | No | No | 1.7 | 102,860 | 174.86 k | 167,860 |
16 Mar 23 | Nissim Darvish | Option to Purchase American Depositary Shares American Depositary Shares | Grant | Acquire A | No | No | 1.62 | 6,857 | 11.11 k | 6,857 |
16 Mar 23 | Neil Harris Cohen | Option to Purchase American Depositary Shares American Depositary Shares | Grant | Acquire A | No | No | 1.62 | 6,875 | 11.14 k | 6,875 |
8 Nov 22 | Sigal Fatal | American Depositary Shares | Grant | Acquire A | No | No | 2.11 | 29,400 | 62.03 k | 65,000 |
16 Jun 22 | Jill M. Quigley | American Depositary Shares | Grant | Acquire A | No | No | 3.25 | 13,640 | 44.33 k | 13,640 |
7 Mar 22 | Nissim Darvish | Option to Purchase American Depositary Shares American Depositary Shares | Grant | Acquire A | No | No | 3.53 | 6,820 | 24.07 k | 6,820 |
7 Mar 22 | Neil Harris Cohen | Option to Purchase American Depositary Shares American Depositary Shares | Grant | Acquire A | No | No | 3.53 | 6,820 | 24.07 k | 6,820 |
11 Nov 21 | Sigal Fatal | American Depositary Shares | Grant | Acquire A | No | No | 9.83 | 35,600 | 349.95 k | 35,600 |
19 Apr 21 | Nissim Darvish | Option to Purchase American Depositary Shares American Depositary Shares | Grant | Acquire A | No | No | 27.26 | 11,884 | 323.96 k | 11,884 |
News
Chemomab Reports New Peer-Reviewed Publication Reinforcing The Clinical Association Of Its CCL24 Target with Disease Severity and Mortality In Systemic Sclerosis
18 Apr 24
Chemomab Bagged New European Patent for CM-101, Its First-in Class Monoclonal Antibody in Phase 2 Clinical Development for Primary Sclerosing Cholangitis
25 Mar 24
Oppenheimer Maintains Perform on Chemomab Therapeuticsto Perform
8 Mar 24
Chemomab Therapeutics Q4 EPS $(0.26) Up From $(0.72) YoY
7 Mar 24
Earnings Scheduled For March 7, 2024
7 Mar 24
Press releases
Chemomab to Host Virtual Key Opinion Leader Webinar on Primary Sclerosing Cholangitis on April 10, 2024
2 Apr 24
Chemomab Awarded New European Patent for CM-101, Its First-in Class Monoclonal Antibody in Phase 2 Clinical Development for Primary Sclerosing Cholangitis
25 Mar 24
Chemomab Therapeutics Announces Year End and Fourth Quarter 2023 Financial Results and Provides a Corporate Update
7 Mar 24
Chemomab Therapeutics to Participate in Leerink Global BioPharma Conference
5 Mar 24
Chemomab Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results and Provide a Business Update
14 Feb 24